The drug targets CD38, not IFNAR1. After binding CD38 on cells, its IFN-alpha payload engages IFNAR1/2 to trigger type I interferon signaling that can cause antiproliferation/apoptosis in those CD38-bound cells; IFNAR1-expressing cells are not directly targeted.